secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001493152-26-008442
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified
--------------------------------------------------------------------------------

- Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.
- Restatement adds $28.7M liability and loss on initial recognition in Q2; net loss restated to $30.2M from $1.4M.
- For Q3, change in fair value of Greenshoe Rights added $11.4M income; net loss restated to $22.6M from $5.3M.
- Greenshoe Rights liability extinguished and reclassified to equity in September 2025 after redemption rights waiver.
- Company plans to file amended 10-Qs for affected periods and includes restated data in 2025 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226008442/0001493152-26-008442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226008442/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer